1477 Results

People

  1. Motzer
    Motzer
  2. Hudis
    Hudis
  3. Aghajanian
    Aghajanian
  4. O'Reilly
    O'Reilly
  5. Kris
    Kris
  6. Scher
    Scher
  7. Panageas
    Panageas
  8. Saltz
    Saltz
  9. Schwartz
    Schwartz
  10. Kelsen
    Kelsen

Groups

  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)
  7. Epidemiology and Biostatistics (194)
  8. Biostatistics Service (169)
  9. Gastrointestinal Oncology Service (160)
  10. Population Sciences Research Program (158)
  1. "fatigue"
Formats
  1. Journal Article (1402)
  2. Review (38)
  3. Research Letter (13)
  4. Editorial (10)
  5. Conference Paper (5)
  6. Guidelines (4)
  7. Correspondence (3)
  8. Book Section (2)
Groups
  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)

More Groups

People
  1. Robert Motzer (85)
  2. Clifford Hudis (49)
  3. Carol Aghajanian (46)
  4. Eileen O'Reilly (46)
  5. Howard Scher (44)
  6. Mark Kris (44)

More People

Years
  1. 2025 (60)
  2. 2024 (132)
  3. 2023 (89)
  4. 2022 (46)
  5. 2021 (33)
  6. 2020 (85)

More Years

Publications
  1. Journal of Clinical Oncology (108)
  2. Clinical Cancer Research (82)
  3. Cancer (63)
  4. Lancet Oncology (50)
  5. Gynecologic Oncology (41)
  6. Annals of Oncology (37)

More Publications

Publishers
  1. Elsevier Inc. (244)
  2. Springer (133)
  3. American Society of Clinical Oncology (114)
  4. Elsevier Science, Inc. (108)
  5. Oxford University Press (101)
  6. American Association for Cancer Research (89)

More Publishers

Results (1477)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia
    Journal Article

    Shah, N. N.; Bhojwani, D.; August, K.; Baruchel, A.; Bertrand, Y.; Boklan, J.; Dalla-Pozza, L.; Dennis, R.; Hijiya, N.; Locatelli, F.; more...
    Pediatric Blood and Cancer (2020)

    Fulltext@MSK | Save
  • A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer
    Journal Article

    Cadoo, K. A.; Grisham, R. N.; O'Cearbhaill, R. E.; Boucicaut, N. N.; Henson, M.; Iasonos, A.; Zhou, Q.; Sarasohn, D. M.; Gallagher, J.; Kravetz, S.; more...
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • Larotrectinib in patients with TRK fusion-positive solid tumours: A pooled analysis of three phase 1/2 clinical trials
    Journal Article

    Hong, D. S.; DuBois, S. G.; Kummar, S.; Farago, A. F.; Albert, C. M.; Rohrberg, K. S.; van Tilburg, C. M.; Nagasubramanian, R.; Berlin, J. D.; Federman, N.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: The ANNOUNCE randomized clinical trial
    Journal Article

    Tap, W. D.; Wagner, A. J.; Schöffski, P.; Martin-Broto, J.; Krarup-Hansen, A.; Ganjoo, K. N.; Yen, C. C.; Abdul Razak, A. R.; Spira, A.; Kawai, A.; more...
    JAMA - Journal of the American Medical Association (2020)

    Fulltext@MSK | Save
  • Phase I study of trifluridine/tipiracil plus irinotecan and bevacizumab in advanced gastrointestinal tumors
    Journal Article

    Varghese, A. M.; Cardin, D. B.; Hersch, J.; Benson, A. B.; Hochster, H. S.; Makris, L.; Hamada, K.; Berlin, J. D.; Saltz, L. B.
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Acalabrutinib and its therapeutic potential in the treatment of chronic lymphocytic leukemia: A short review on emerging data
    Review

    Isaac, K.; Mato, A. R.
    Cancer Management and Research (2020)

    Fulltext@MSK | Save
  • Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: Results from the CheckMate 032 randomized cohort
    Journal Article

    Ready, N. E.; Ott, P. A.; Hellmann, M. D.; Zugazagoitia, J.; Hann, C. L.; de Braud, F.; Antonia, S. J.; Ascierto, P. A.; Moreno, V.; Atmaca, A.; more...
    Journal of Thoracic Oncology (2020)

    Fulltext@MSK | Save
  • Subgroup analysis of older patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trial
    Journal Article

    Younger, E.; Ballman, K.; Lu, Y.; Pápai, Z.; Van Tine, B. A.; Attia, S.; Schöffski, P.; Reinke, D.; Tap, W. D.; Jones, R. L.
    Journal of Geriatric Oncology (2020)

    Fulltext@MSK | Save
  • Clinician vs patient reporting of baseline and postbaseline symptoms for adverse event assessment in cancer clinical trials
    Research Letter

    Atkinson, T. M.; Dueck, A. C.; Satele, D. V.; Thanarajasingam, G.; Lafky, J. M.; Sloan, J. A.; Basch, E.
    JAMA Oncology (2020)

    Fulltext@MSK | Save
  • Assessment of adverse events from the patient perspective in a phase 3 metastatic castration-resistant prostate cancer clinical trial
    Journal Article

    Dueck, A. C.; Scher, H. I.; Bennett, A. V.; Mazza, G. L.; Thanarajasingam, G.; Schwab, G.; Weitzman, A. L.; Rogak, L. J.; Basch, E.
    JAMA Oncology (2020)

    Fulltext@MSK | Save